tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Andrew Peters, 40 are a BUY (85.11%), 6 are a HOLD (12.77%), 1 are a SELL (2.13%).
Analyst Andrew Peters, carries an average stock price target met ratio of 82.41% that have a potential upside of 40.27% achieved within 593 days. Previously, Andrew Peters worked at DEUTSCHE BANK, UBS.
Andrew Peters’s has documented 97 price targets and ratings displayed on 13 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ESPR, Esperion Therapeutics at 03-May-2018.
Analyst best performing recommendations are on IMGN (IMMUNOGEN).
The best stock recommendation documented was for IMGN (IMMUNOGEN) at 6/11/2014. The price target of $13 was fulfilled within 1 day with a profit of $0.87 (7.17%) receiving and performance score of 71.72.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 04-Aug-2022
$122
$63.49 (108.51%)
$124
13 days ago
(21-Oct-2026)
18/29 (62.07%)
$66.79 (120.97%)
372
Buy Since 24-Oct-2022
$87
$28.49 (48.69%)
14 days ago
(20-Oct-2026)
1/11 (9.09%)
$30.56 (54.15%)
80
Buy Since 25-Nov-2014
$88
$29.49 (50.40%)
$125
19 days ago
(15-Oct-2026)
3/5 (60%)
$31.95 (57.00%)
566
Buy Since 04-Mar-2019
$114
$55.49 (94.84%)
$111
20 days ago
(14-Oct-2026)
6/16 (37.5%)
$58.86 (106.75%)
381
Buy Since 26-Apr-2021
$109
$50.49 (86.29%)
$120
22 days ago
(12-Oct-2026)
5/9 (55.56%)
$54.2 (98.91%)
279
